文献速递瓣膜病与结构性心脏病心力衰竭与心肌病

堪萨斯城心肌病问卷在三尖瓣反流患者中的验证

Validation of the Kansas City Cardiomyopathy Questionnaire in Patients With Tricuspid Regurgitation.
PubMed 文献 · JAMA Cardiol · 2025-01-01

本研究汇总11项经导管三尖瓣介入(TTVI)厂商赞助试验中2693例重度三尖瓣反流(TR)患者数据,评估堪萨斯城心肌病问卷(KCCQ)的心理测量学性能。结果显示KCCQ各领域内部一致性良好、可重复性佳、对TTVI后变化反应灵敏,且与临床事件相关,支持其用于重度TR患者症状、功能与生活质量的评估。

要点

  • KCCQ在重度TR患者中内部一致性、可重复性、反应性与效度均良好。
  • TTVI后1个月KCCQ各领域及汇总评分大幅改善,提示对治疗变化敏感。
  • KCCQ总分每降低10分与死亡和心衰住院风险升高相关。

核心结论

  • KCCQ在重度TR患者中具有良好的心理测量学性能,包括信度、反应性与效度。
  • 数据支持将KCCQ用于重度TR患者症状、功能与生活质量的测量,以及评估TTVI等干预的效果。

研究设计与样本

  • 汇总11项厂商赞助的TTVI试验中重度TR患者数据,数据经美国食品药品监督管理局统一并匿名化后由独立中心分析。
  • 研究队列共2693例患者,其中单臂研究1517例、随机研究1176例;数据收集于2015年12月至2023年4月,分析于2023年7月至10月。
  • 预设分析包括内部一致性、可重复性、反应性、结构效度与预测效度。

主要发现

  • 患者平均(SD)年龄78.6(8.0)岁,2693例中1658例(61.6%)为女性,基线KCCQ总体汇总(KCCQ-OS)平均(SD)评分为50(23)。
  • 临床稳定患者在1至6个月间KCCQ各领域及汇总评分平均变化较小(差异为-0.1至1.9分),显示可重复性。
  • 接受TTVI的患者治疗后1个月各领域及汇总评分大幅改善(平均变化12.1-21.4分),显示良好的感知反应性。
  • 各领域与最佳可用参照测量比较时结构效度中等偏强(Spearman相关系数,0.47-0.69)。

关键数值与推荐

  • 可重复性:临床稳定患者1至6个月评分平均变化为-0.1至1.9分。
  • 反应性:TTVI后1个月评分平均变化为12.1-21.4分。
  • 结构效度:Spearman相关系数为0.47-0.69。
  • 预测效度:KCCQ-OS每降低10分,死亡风险比1.34(95%CI,1.22-1.47),心衰住院风险比1.24(95%CI,1.17-1.31)。

临床怎么用

  • 可将KCCQ用于重度TR患者症状、功能与生活质量的标准化评估。
  • 可在严格对照试验中用KCCQ评估TTVI等干预对患者健康状态的影响。
  • KCCQ-OS评分较低提示死亡与心衰住院风险较高,可用于风险分层参考。

局限性

  • 数据来自厂商赞助的TTVI试验,患者选择与试验环境可能影响外推性。
  • 未报告非TTVI治疗或未入选试验的重度TR患者数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Improving patients' health status is a key goal of treating tricuspid regurgitation (TR). The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a heart failure disease-specific health status measure used to capture the health status impact of TR and the benefit of transcatheter tricuspid valve intervention (TTVI), but its validity in this clinical setting is unknown. OBJECTIVE: To evaluate the psychometric properties of the KCCQ in patients with TR. DESIGN, SETTING, AND PARTICIPANTS: Data were pooled from patients with severe TR enrolled in 11 manufacturer-sponsored trials of TTVI. The data were transferred to the US Food and Drug Administration to harmonize and anonymize prior to analysis by an independent center. Data were collected from December 2015 to April 2023, and data analysis was performed from July to October 2023. MAIN OUTCOMES AND MEASURES: Prespecified analyses included evaluation of internal consistency, reproducibility, responsiveness, construct validity, and predictive validity. Outcomes were determined using Cronbach α, score comparisons, intraclass correlation, Cohen d, Spearman correlations with best available reference measures, and association of scores and changes in scores with risk of subsequent clinical events. RESULTS: The study cohort was composed of 2693 patients enrolled in either single-arm (n = 1517) or randomized (n = 1176) investigations of TTVI. Mean (SD) patient age was 78.6 (8.0) years, 1658 of 2693 patients (61.6%) were female, and the mean (SD) baseline KCCQ Overall Summary (KCCQ-OS) score was 50 (23). There was strong internal consistency within individual domains (Cronbach α, .77-.83). Among clinically stable patients between 1 and 6 months, there were small mean changes in KCCQ domain and summary scores (differences of -0.1 to 1.9 points), demonstrating reproducibility. In contrast, domain and summary scores of patients who underwent TTVI showed large improvements at 1 month after treatment (mean changes, 12.1-21.4 points), indicating excellent perceived responsiveness. Construct validity was moderately strong when domains were compared with best available reference measures (Spearman correlations, 0.47-0.69). In both cross-sectional and longitudinal analyses, the KCCQ-OS was associated with clinical events, with lower scores associated with an increased risk of mortality (hazard ratio, 1.34 per 10-point decrement; 95% CI, 1.22-1.47) and heart failure hospitalization (hazard ratio, 1.24 per 10-point decrement; 95% CI, 1.17-1.31). CONCLUSIONS AND RELEVANCE: In this cohort study, the KCCQ had strong psychometric properties in patients with severe TR, including reliability, responsiveness, and validity. These data support use of the KCCQ in patients with severe TR as a measure of their symptoms, function, and quality of life and also for assessing the impact of interventions, such as TTVI, in rigorously controlled trials.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Arnold SV, Spertus JA, Gosch K, et al. Validation of the Kansas City Cardiomyopathy Questionnaire in Patients With Tricuspid Regurgitation. JAMA Cardiol. 2025. PMID: 39476153. doi:10.1001/jamacardio.2024.4266

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。